Belimumabe para o tratamento do lúpus eritematoso sistêmico: uma avaliação da tecnologia

Dennys Ricardo Malouf; Carlos Henrique Botelho; Mabel Fernandes Figueiró; Tereza Setsuko Toma

doi:10.52753/bis.v16i1.37380

Vol. 16 No. 1 (2015), Artigos

Vol. 16 No. 1 (2015)

Belimumab for the treatment fo systemic lupus erythematosus: an assessment of technology

Artigos

https://doi.org/10.52753/bis.v16i1.37380

Published 2015-07-01

Dennys Ricardo Malouf
Carlos Henrique Botelho
Mabel Fernandes Figueiró⁺⁻
Tereza Setsuko Toma⁺⁻

Dennys Ricardo Malouf

Carlos Henrique Botelho

Mabel Fernandes Figueiró

Hospital do Coração

Tereza Setsuko Toma

Secretaria de Estado da Saúde de São Paulo. Instituto de Saúde

artigo (Português (Brasil))

Keywords

Systemic lupus erythematosus; Belimumab; Benlysta

How to Cite

Malouf, D. R., Botelho, C. H., Fernandes Figueiró, M., & Setsuko Toma, T. (2015). Belimumab for the treatment fo systemic lupus erythematosus: an assessment of technology. Boletim Do Instituto De Saúde - BIS, 16(1), 121–126. https://doi.org/10.52753/bis.v16i1.37380

Abstract

Systemic lupus erythematosus is a chronic inflammatory disease of unknown cause and autoimmune feature. The development of the disease has been linked to genetic predisposition, environmental and hormonal factors, and 90% of patients are women. In 2012, ANVISA granted the registration of belimumab, a monoclonal antibody indicated as an adjunct in adult patients with lupus and lack of response to standard treatment (anti-inflammatory drugs glucocorticoids, antimalarials and immunosuppressants). The objective of this study was to analyze the efficacy and safety of belimumab in the treatment of lupus in adults. Two systematic reviews indicated that belimumab 10 mg/kg in the 52-week treatment regimen was effective in reducing disease activity, and it is necessary to treat nine patients for one patient benefited. There were no significant differences in adverse events between the groups of patients.

https://doi.org/10.52753/bis.v16i1.37380

artigo (Português (Brasil))

References

1. BMJ Best Practice. Lúpus eritematoso sistêmico. [acesso em 9 out 2014]. Disponível em: http://brasil.bestpractice. bmj.com/best-practice/monograph/103.html
2. Borba EF, Latorre LC, Brenol JCT, Kayser C, Silva NA, Zimmermann AF et al. Consenso de Lúpus Eritematoso Sistêmico. Rev Bras Reumatol. 2008; 48(4):196-207. [acesso em 9 out 2014]. Disponível em: http://www.scielo. br/pdf/rbr/v48n4/v48n4a02.pdf
3. Borba HHL, Wiens A, de Souza TT, Correr CJ, Pontarolo R. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and metaanalysis. BioDrugs. 2014; 28(2):211-228.
4. Enríquez-Mejía MG. Fisiopatología del lupus eritematoso sistémico. Revista de Medicina e Investigación. 2013; 1(1):8-16. [acesso em 9 out 2014]. Disponível em: http://apps.elsevier.es/watermark/
ctl_servlet?_f=10&pident_ articulo=90165398&pident_ usuario=0& pcontactid=&pident_revista=353&ty=5& accio n=L&origen=zonadelectura&web=zl.elsevier.es&lan=es& fi chero=353v01n01a90165398pdf001.pdf
5. Kandala NB, Connock M, Grove A, Sutcliffe P, Mohiuddin S, Hartley L et al. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open. 2013; 3(7):e002852. [acesso em 22 dez 2014]. Disponível em: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717447/ pdf/bmjopen-2013-002852.pdf
6. Luijten KM, Tekstra J, Bijlsma JWJ, Bijl M. The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012; 11(5):326-329.
7. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria 100, de 7 de fevereiro de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas do Lúpus Eritematoso Sistêmico. Diario Oficial da União, 8 fev. 2013. [acesso em 22 dez 2014]. Disponível em: http://bvsms.saude.gov.br/ bvs/saudelegis/sas/2013/prt0100_07_02_2013.html
8. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de Pareceres Técnico-Científicos. Brasília (DF); 2011 [acesso em 15 abr 2014]. Disponível em: http://200.214.130.94/ rebrats/publicacoes/DiretrizesPTC.pdf
9. Sato EI, Bonfá ED, Costallat LTL, Silva NA, Brenol JCT, Santiago MB et al. Consenso brasileiro para o tratamento do lúpus eritematoso sistêmico (LES). Rev Bras Reumatol. 2002; 42(6):362-70. [acesso em 9 out 2014]. Disponível em: http://www.cidmed.com.br/pdf/lupus.pdf
10. Sharif MO, Sharif FNJ, Ali H, Ahmed F. Systematic reviews explained: AMSTAR – how to tell the good from the bad and the ugly. OHDM. 2013; 12(1):9-16. [acesso em 22 dez 2014]. Disponível em: http://omicsonline.com/open-ac cess/2247-2452/2247-2452-12-491.pdf?aid=12933
11. Specchia ML, Waure C, Gualano MR, Doria A, Turchetti G, Pippo L et al. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. Biomed Research International. 2014; 16:1-9. [acesso em 22 dez 2014] Disponível em: http://www.hindawi.com/journals/bmri/2014/704207/ 12. U.S. Food and Drug Administration. Arthritis Advisory Committee Meeting Briefing Document for the 16 November 2010. Belimumab BENLYSTA® (belimumab), Treatment of Systemic Lupus Erythematosus – BLA 125370, 13 oct. 2010. Estados Unidos; 2010. [acesso em 9 out 2014] Disponível em: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisAdvisoryCommittee/UCM233581.pdf